13C6-Leu Amyloid Beta 1-42 Peptide

Product Name
13C6-Leu Amyloid Beta 1-42 Peptide
Product Quantity
4 mg
Catalog Number
LT8735
Sequence
DAEFRHDSGY EVHHQK(L*)VFF AEDVGSNKGA IIG(L*)MVGGVV IA
Purity
>95%
Modifications
13C6-Leu at positions 17 and 34
Peptide Type
Amyloid-beta research peptide
Published / Parent Sequence
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
Product Description

13C6-Leu Amyloid Beta 1-42 Peptide is derived from the amyloid-beta sequence generated from human amyloid-beta precursor protein (APP). The canonical Aβ region is publicly curated within human APP UniProtKB entry P05067.

Amyloid Beta Research Peptides

Amyloid-beta peptides are central research reagents in studies of peptide aggregation, amyloid fibril formation, membrane interactions, proteolytic processing, antibody recognition, and analytical assay development. Aβ1-40 and Aβ1-42 are the two most widely studied C-terminal forms.

Aβ1-42 contains two additional C-terminal residues relative to Aβ1-40 and generally displays stronger aggregation propensity under many experimental conditions. Sequence, concentration, solvent history, pre-treatment, and incubation conditions can all strongly affect aggregation state.

Aβ1-42 Parent Sequence

DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA

Stable-Isotope 13C6-Leucine Labeling

LT8735 contains 13C6-labeled leucine residues at positions 17 and 34 of Aβ1-42. Stable-isotope-labeled peptides are useful as analytical reference materials and internal standards in mass-spectrometric workflows because the labeled peptide can closely mimic the chromatographic and ionization behavior of the unlabeled analyte while remaining distinguishable by mass.

This format may support LC-MS method development, recovery studies, quantitative assay optimization, and peptide analytical workflows.

Potential Research Applications

  • Amyloid aggregation studies
  • LC-MS analytical methods
  • Antibody binding assays
  • Peptide-protein interaction studies
  • Fluorescent or chemical conjugation
  • Reference-standard development

For aggregation-sensitive studies, peptide handling and pre-treatment procedures should be standardized across experiments.

References

UniProt Consortium APP - Amyloid-beta precursor protein - Homo sapiens. UniProtKB P05067.
Public source / publication

Related LifeTein Services

Custom Peptide Synthesis
Fluorescent Peptide Labeling
Peptide Click Chemistry and Conjugation
Peptide Carrier Protein Conjugation

Research Use Only. Not for human, diagnostic, clinical, or therapeutic use.

Scientific Background

13C6-Leu Amyloid Beta 1-42 Peptide is a synthetic amyloid-beta (Aβ) research peptide. Amyloid-beta peptides are proteolytic products of amyloid precursor protein. Sequence length and residue composition strongly influence aggregation: Aβ42 generally aggregates more rapidly than Aβ40, and C-terminal fragments containing residues in the 34-42 region can adopt stable beta-structure. Truncated, reverse-sequence, isotopically labeled, or chemically modified Aβ constructs are therefore best interpreted as distinct research reagents rather than assumed equivalents of native Aβ40 or Aβ42.

Research Applications
  • amyloid aggregation and fibrillization studies
  • LC-MS/HPLC analytical reference work
  • Aβ sequence-length and modification comparisons
  • antibody, binding, and assay controls
Experimental Notes

The exact sequence, phosphorylation state, residue numbering, terminal modifications, labels, and species context should be matched to the intended assay. Sequence motifs support experimental interpretation but do not by themselves establish absolute enzyme specificity or native biological activity.

Selected References
  1. Sequence determinants of enhanced amyloidogenicity of Aβ42 relative to Aβ40
  2. Molecular determinants of amyloid deposition: synthetic beta-protein fragments
  3. Impact of sequence on assembly of short amyloid peptides
  • 1 Units in Stock
Ask a Question

Add to Cart: